Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
Trial ID or NCT#
NCT04585490
Status
RECRUITING
Purpose
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Official Title
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC
Investigator(s)
Maximilian Diehn, MD, PhD
Radiation oncologist
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Mohana Roy
Medical oncologist,
Thoracic specialist
Clinical Assistant Professor, Medicine - Oncology
Contact us to find out if this trial is right for you.
Contact
Samantha Wong
650-498-8495
View on ClinicalTrials.gov
